Equity Profile

AXSM

Axsome Therapeutics, Inc.

Health CarePharmaceuticals$11.7B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to revenue.

N/A

Revenue Growth

Revenue growth will indicate the company’s ability to expand its market presence and the success of its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $12 billion, its work is significant in addressing unmet medical needs in mental health and pain management.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1 2026, Axsome reported an EPS of -$1.26, which was worse than the expected -$0.85, resulting in a significant surprise. Despite this, the stock rose by 8.31% the next day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as Axsome has shown volatility in its earnings history, with a 50% EPS beat rate. Investors are cautious due to recent misses but remain hopeful for potential growth.

Bull Case

If Axsome can demonstrate improved revenue and a smaller EPS loss than expected, it could signal strong demand for its products and lead to a positive market reaction.

Bear Case

Conversely, if the company reports a larger EPS loss and weak revenue growth, it could raise concerns about its future viability and lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in assessing the company's financial health and operational efficiency, especially after the significant miss last quarter.

What is the revenue growth compared to previous quarters?

Revenue growth will provide insight into market demand for Axsome's products and its ability to capture market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Axsome to improve its financial metrics this quarter, particularly in light of recent product developments.

Supporting Evidence

The options market is pricing a 19.2% move, suggesting expectations for volatility that may not align with the company's actual performance.

Historically, Axsome has shown a tendency to surprise positively, even after misses, which could lead to a favorable outcome this quarter.

Key Risk

If Axsome reports an EPS loss smaller than expected, it could shift the narrative towards recovery and growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Axsome can stabilize its financial performance and regain investor confidence.

Bull Confirmed If

A smaller EPS loss than -$1.26, ideally moving towards breakeven, would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$1.26 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests the stock could rise by an average of +2.93%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.

Miss

If the company misses expectations, history suggests a potential drop of around +1.28%, which could raise concerns about its future outlook.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on cost management strategies and operational efficiencies.
3Insights into market demand for Axsome's therapies and any new partnerships.
4Details on regulatory progress for any upcoming drug approvals.
5Responses to analyst questions regarding competitive pressures in the pharmaceutical market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to revenue.

N/A

Revenue Growth

Revenue growth will indicate the company’s ability to expand its market presence and the success of its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as Axsome has shown volatility in its earnings history, with a 50% EPS beat rate. Investors are cautious due to recent misses but remain hopeful for potential growth.

Bull Case

If Axsome can demonstrate improved revenue and a smaller EPS loss than expected, it could signal strong demand for its products and lead to a positive market reaction.

Bear Case

Conversely, if the company reports a larger EPS loss and weak revenue growth, it could raise concerns about its future viability and lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in assessing the company's financial health and operational efficiency, especially after the significant miss last quarter.

What is the revenue growth compared to previous quarters?

Revenue growth will provide insight into market demand for Axsome's products and its ability to capture market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Axsome to improve its financial metrics this quarter, particularly in light of recent product developments.

Supporting Evidence

The options market is pricing a 19.2% move, suggesting expectations for volatility that may not align with the company's actual performance.

Historically, Axsome has shown a tendency to surprise positively, even after misses, which could lead to a favorable outcome this quarter.

Key Risk

If Axsome reports an EPS loss smaller than expected, it could shift the narrative towards recovery and growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Axsome can stabilize its financial performance and regain investor confidence.

Bull Confirmed If

A smaller EPS loss than -$1.26, ideally moving towards breakeven, would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$1.26 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests the stock could rise by an average of +2.93%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.

Miss

If the company misses expectations, history suggests a potential drop of around +1.28%, which could raise concerns about its future outlook.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on cost management strategies and operational efficiencies.
3Insights into market demand for Axsome's therapies and any new partnerships.
4Details on regulatory progress for any upcoming drug approvals.
5Responses to analyst questions regarding competitive pressures in the pharmaceutical market.